RecruitingPhase 1NCT07232589
A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)
A Study to Evaluate the Effect of Multiple Oral Doses of Diltiazem on the Single-Dose Pharmacokinetics of Nemtabrutinib in Healthy Participants.
Sponsor
Merck Sharp & Dohme LLC
Enrollment
24 participants
Start Date
Dec 8, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria2
- Be in good health
- BMI between 18.5 and 32 kg/m2, inclusive
Exclusion Criteria2
- History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological (history of a bleeding disorder, abnormal bleeding or a hereditary or acquired coagulation or platelet disorder), hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke, intercranial hemorrhage, and chronic seizures) abnormalities or diseases
- History of cancer (malignancy)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNemtabrutinib
Oral administration
DRUGDiltiazem
Oral administration
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07232589
Related Trials
Predicting Future Errors During Skill Performance
NCT067072071 location
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Imaging Techniques in MRI
NCT011305451 location
A Study of [14C]-LY4064809 in Healthy Participants
NCT075195251 location
Study of New Magnetic Resonance Imaging Methods of the Brain
NCT000045771 location